- Home
- BHVN vs DNTH Comparison
BHVN vs DNTH Comparison
Compare BHVN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHVN
- DNTH
- Stock Information
- Founded
- BHVN 2013
- DNTH 2015
- Country
- BHVN United States
- DNTH United States
- Employees
- BHVN N/A
- DNTH N/A
- Industry
- BHVN Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- BHVN Health Care
- DNTH Health Care
- Exchange
- BHVN Nasdaq
- DNTH Nasdaq
- Market Cap
- BHVN 1.5B
- DNTH 1.5B
- IPO Year
- BHVN 2017
- DNTH N/A
- Fundamental
- Price
- BHVN $14.72
- DNTH $38.88
- Analyst Decision
- BHVN Strong Buy
- DNTH Strong Buy
- Analyst Count
- BHVN 16
- DNTH 10
- Target Price
- BHVN $52.13
- DNTH $66.38
- AVG Volume (30 Days)
- BHVN 2.0M
- DNTH 989.4K
- Earning Date
- BHVN 11-11-2025
- DNTH 11-06-2025
- Dividend Yield
- BHVN N/A
- DNTH N/A
- EPS Growth
- BHVN N/A
- DNTH N/A
- EPS
- BHVN N/A
- DNTH N/A
- Revenue
- BHVN N/A
- DNTH $4,854,000.00
- Revenue This Year
- BHVN N/A
- DNTH N/A
- Revenue Next Year
- BHVN $2,195.07
- DNTH N/A
- P/E Ratio
- BHVN N/A
- DNTH N/A
- Revenue Growth
- BHVN N/A
- DNTH 17.87
- 52 Week Low
- BHVN $12.79
- DNTH $13.37
- 52 Week High
- BHVN $55.70
- DNTH $39.70
- Technical
- Relative Strength Index (RSI)
- BHVN 49.97
- DNTH 84.91
- Support Level
- BHVN $13.41
- DNTH $36.00
- Resistance Level
- BHVN $14.23
- DNTH $24.81
- Average True Range (ATR)
- BHVN 0.86
- DNTH 2.76
- MACD
- BHVN -0.17
- DNTH 1.05
- Stochastic Oscillator
- BHVN 33.98
- DNTH 95.37
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.